Induction of phase I, II and III drug metabolism/transport by xenobiotics
- PMID: 15832810
- DOI: 10.1007/BF02977789
Induction of phase I, II and III drug metabolism/transport by xenobiotics
Abstract
Drug metabolizing enzymes (DMEs) play central roles in the metabolism, elimination and detoxification of xenobiotics and drugs introduced into the human body. Most of the tissues and organs in our body are well equipped with diverse and various DMEs including phase I, phase II metabolizing enzymes and phase III transporters, which are present in abundance either at the basal unstimulated level, and/or are inducible at elevated level after exposure to xenobiotics. Recently, many important advances have been made in the mechanisms that regulate the expression of these drug metabolism genes. Various nuclear receptors including the aryl hydrocarbon receptor (AhR), orphan nuclear receptors, and nuclear factor-erythoroid 2 p45-related factor 2 (Nrf2) have been shown to be the key mediators of drug-induced changes in phase I, phase II metabolizing enzymes as well as phase III transporters involved in efflux mechanisms. For instance, the expression of CYP1 genes can be induced by AhR, which dimerizes with the AhR nuclear translocator (Arnt), in response to many polycyclic aromatic hydrocarbon (PAHs). Similarly, the steroid family of orphan nuclear receptors, the constitutive androstane receptor (CAR) and pregnane X receptor (PXR), both heterodimerize with the retinoid X receptor (RXR), are shown to transcriptionally activate the promoters of CYP2B and CYP3A gene expression by xenobiotics such as phenobarbital-like compounds (CAR) and dexamethasone and rifampin-type of agents (PXR). The peroxisome proliferator activated receptor (PPAR), which is one of the first characterized members of the nuclear hormone receptor, also dimerizes with RXR and has been shown to be activated by lipid lowering agent fibrate-type of compounds leading to transcriptional activation of the promoters on CYP4A gene. CYP7A was recognized as the first target gene of the liver X receptor (LXR), in which the elimination of cholesterol depends on CYP7A. Farnesoid X receptor (FXR) was identified as a bile acid receptor, and its activation results in the inhibition of hepatic acid biosynthesis and increased transport of bile acids from intestinal lumen to the liver, and CYP7A is one of its target genes. The transcriptional activation by these receptors upon binding to the promoters located at the 5-flanking region of these CYP genes generally leads to the induction of their mRNA gene expression. The physiological and the pharmacological implications of common partner of RXR for CAR, PXR, PPAR, LXR and FXR receptors largely remain unknown and are under intense investigations. For the phase II DMEs, phase II gene inducers such as the phenolic compounds butylated hydroxyanisol (BHA), tert-butylhydroquinone (tBHQ), green tea polyphenol (GTP), (-)-epigallocatechin-3-gallate (EGCG) and the isothiocyanates (PEITC, sulforaphane) generally appear to be electrophiles. They generally possess electrophilic-mediated stress response, resulting in the activation of bZIP transcription factors Nrf2 which dimerizes with Mafs and binds to the antioxidant/electrophile response element (ARE/EpRE) promoter, which is located in many phase II DMEs as well as many cellular defensive enzymes such as heme oxygenase-1 (HO-1), with the subsequent induction of the expression of these genes. Phase III transporters, for example, P-glycoprotein (P-gp), multidrug resistance-associated proteins (MRPs), and organic anion transporting polypeptide 2 (OATP2) are expressed in many tissues such as the liver, intestine, kidney, and brain, and play crucial roles in drug absorption, distribution, and excretion. The orphan nuclear receptors PXR and CAR have been shown to be involved in the regulation of these transporters. Along with phase I and phase II enzyme induction, pretreatment with several kinds of inducers has been shown to alter the expression of phase III transporters, and alter the excretion of xenobiotics, which implies that phase III transporters may also be similarly regulated in a coordinated fashion, and provides an important mean to protect the body from xenobiotics insults. It appears that in general, exposure to phase I, phase II and phase III gene inducers may trigger cellular "stress" response leading to the increase in their gene expression, which ultimately enhance the elimination and clearance of these xenobiotics and/or other "cellular stresses" including harmful reactive intermediates such as reactive oxygen species (ROS), so that the body will remove the "stress" expeditiously. Consequently, this homeostatic response of the body plays a central role in the protection of the body against "environmental" insults such as those elicited by exposure to xenobiotics.
Similar articles
-
Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.Curr Drug Metab. 2002 Oct;3(5):481-90. doi: 10.2174/1389200023337171. Curr Drug Metab. 2002. PMID: 12369894 Review.
-
Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE).Drug Metab Rev. 2001 Aug-Nov;33(3-4):255-71. doi: 10.1081/dmr-120000652. Drug Metab Rev. 2001. PMID: 11768769 Review.
-
Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes.Clin Pharmacokinet. 2003;42(15):1331-57. doi: 10.2165/00003088-200342150-00003. Clin Pharmacokinet. 2003. PMID: 14674787 Review.
-
Establishing Transcriptional Signatures to Differentiate PXR-, CAR-, and AhR-Mediated Regulation of Drug Metabolism and Transport Genes in Cryopreserved Human Hepatocytes.J Pharmacol Exp Ther. 2018 May;365(2):262-271. doi: 10.1124/jpet.117.247296. Epub 2018 Feb 12. J Pharmacol Exp Ther. 2018. PMID: 29440451
-
Induction profile of rat organic anion transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme inducers that activate gene expression through ligand-activated transcription factor pathways.J Pharmacol Exp Ther. 2002 Jan;300(1):206-12. doi: 10.1124/jpet.300.1.206. J Pharmacol Exp Ther. 2002. PMID: 11752118
Cited by
-
PPARα as a Transcriptional Regulator for Detoxification of Plant Diet-Derived Unfavorable Compounds.PPAR Res. 2012;2012:814945. doi: 10.1155/2012/814945. Epub 2012 Apr 19. PPAR Res. 2012. PMID: 22577367 Free PMC article.
-
Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1.Mol Cells. 2013 Feb;35(2):151-7. doi: 10.1007/s10059-013-2298-5. Epub 2013 Jan 16. Mol Cells. 2013. PMID: 23329300 Free PMC article.
-
Starvation, detoxification, and multidrug resistance in cancer therapy.Drug Resist Updat. 2012 Feb-Apr;15(1-2):114-22. doi: 10.1016/j.drup.2012.01.004. Epub 2012 Mar 4. Drug Resist Updat. 2012. PMID: 22391012 Free PMC article. Review.
-
Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver.Drug Metab Dispos. 2016 Jul;44(7):999-1004. doi: 10.1124/dmd.115.069252. Epub 2016 Apr 20. Drug Metab Dispos. 2016. PMID: 27098745 Free PMC article.
-
Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells.Naunyn Schmiedebergs Arch Pharmacol. 2015 Jun;388(6):601-12. doi: 10.1007/s00210-015-1101-x. Epub 2015 Feb 24. Naunyn Schmiedebergs Arch Pharmacol. 2015. PMID: 25708948
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous